1. Peri-operative biology in primary breast cancer: a credible therapeutic target

   • Richard R. Love
   • Susan M. Love

   Review 24 March 2016 Pages: 411 - 413

2. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions

   • Claire Johns
   • Susan M. Seav
   • H. Irene Su

   Review 26 March 2016 Pages: 415 - 426

   

3. Neoadjuvant nab-paclitaxel in the treatment of breast cancer

   • Naoto T. Ueno
   • Eleftherios P. Mamounas

   Review Open access 12 April 2016 Pages: 427 - 440

4. Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations

   • Lu Yao
   • Jie Sun
   • Yuntao Xie

   Preclinical study 31 March 2016 Pages: 441 - 445

   

5. SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs

   • Karen Blyth
   • Phil Carter
   • Valerie Speirs

   Preclinical study Open access 15 April 2016 Pages: 447 - 452

   

6. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer

   • Heather Greenlee
   • Katherine D. Crew
   • Dawn L. Hershman

   Clinical trial 25 March 2016 Pages: 453 - 464

   

7. Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study

   • Lori M. van Roozendaal
   • Leonie H. M. Smit
   • Marjolein L. Smidt

   Clinical trial Open access 25 March 2016 Pages: 465 - 472

   

8. Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population

   • Seung Taek Lim
   • Jung Eun Choi
   • Young Jin Suh

   Clinical trial 04 April 2016 Pages: 473 - 483

   

9. Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry

   • Takayuki Iwamoto
   • Hiraku Kumamaru
   • Yutaka Tokuda

   Clinical trial Open access 05 April 2016 Pages: 485 - 494

   

10. Structured reporting ensures complete content and quick detection of essential data in pathology reports of oncological breast resection specimens

    • Konrad Aumann
    • Kathrin Niermann
    • Martin Werner

    Clinical trial 08 April 2016 Pages: 495 - 500

    

11. Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up

    • G. Murtagh
    • T. Lyons
    • J. M. Walshe

    Clinical trial 09 April 2016 Pages: 501 - 506

12. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial

    • Milagros González-Rivera
    • Miriam Lobo
    • Miguel Martin

    Clinical trial 15 April 2016 Pages: 507 - 515

13. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy

    • L. M. van Roozendaal
    • B. Goorts
    • M. L. Smidt

    Clinical trial Open access 15 April 2016 Pages: 517 - 525

    

14. High use of complementary and alternative medicine among a large cohort of women with a family history of breast cancer: the Sister Study

    • Heather Greenlee
    • Christine L. Sardo Molmenti
    • Dale P. Sandler

    Epidemiology 26 March 2016 Pages: 527 - 538

    

15. Prognostic factors in male breast cancer: a population-based study

    • José Pablo Leone
    • Ariel Osvaldo Zwenger
    • Rohit Bhargava

    Epidemiology 02 April 2016 Pages: 539 - 548

    

16. Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy

    • Chalanda N. Evans
    • Noel T. Brewer
    • Suzanne C. O’Neill

    Epidemiology 08 April 2016 Pages: 549 - 555

    

17. Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

    • Jan C. Drooger
    • Bernadette A. M. Heemskerk-Gerritsen
    • Agnes Jager

    Epidemiology Open access 09 April 2016 Pages: 557 - 566

    

18. Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls

    • Kathy Pan
    • Rowan T. Chlebowski
    • Electra D. Paskett

    Epidemiology 13 April 2016 Pages: 567 - 576

    

19. Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer

    • B. Cabarrou
    • L. Belin
    • T. Filleron

    Epidemiology 13 April 2016 Pages: 577 - 585

    

20. The incidence of bone metastasis after early-stage breast cancer in Canada

    • Alexander Liede
    • Katarzyna J. Jerzak
    • Steven A. Narod

    Epidemiology 15 April 2016 Pages: 587 - 595

    

21. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer

    • Young-Ae Kim
    • Hee Jin Lee
    • Gyungyub Gong

    Brief Report 13 April 2016 Pages: 597 - 606

    

22. Erratum to: A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer

    • Sepideh Gholami
    • Andrew Marano
    • Yuman Fong

    Erratum 30 March 2016 Pages: 607 - 608

    

23. Erratum to: FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells

    • Juan Du
    • Lin Li
    • Jun Lu

    Erratum 08 April 2016 Pages: 609 - 610